📊 BIIB Key Takeaways
Investment Thesis
Biogen demonstrates solid operational profitability with 15.7% operating margin and strong free cash flow generation ($2.1B), supported by a healthy balance sheet with 2.68x current ratio and manageable 0.34x debt-to-equity. However, revenue growth is anemic at 2.2% YoY with flat net income growth and diluted EPS declining 21.4%, indicating challenges in product pipeline execution or market competition that offset operational efficiency.
BIIB Strengths
- Strong free cash flow generation at $2.1B with 20.7% FCF margin provides capital flexibility
- Solid liquidity position with 2.68x current ratio and 2.03x quick ratio supporting operational stability
- Healthy interest coverage of 5.8x and conservative 0.34x debt-to-equity ratio indicate low financial distress risk
- Consistent gross margin at 117.7% suggests pricing power and cost management despite sector pressures
BIIB Risks
- Stagnant revenue growth at 2.2% YoY with zero net income growth signals potential product portfolio challenges or market saturation
- Significant EPS decline of 21.4% year-over-year despite flat net income suggests share dilution or unfavorable capital allocation
- Low ROE of 7.1% and ROA of 4.4% indicate modest returns on capital despite substantial asset base of $29.4B
- Elevated gross margin at 117.7% appears anomalous and may indicate accounting irregularities or non-operating gains requiring clarification
Key Metrics to Watch
- Revenue growth trajectory and new product pipeline contribution rates
- Operating margin sustainability and R&D spending efficiency
- Free cash flow consistency and capital allocation strategy
- Return on equity improvement and share dilution trends
BIIB Financial Metrics
💡 AI Analyst Insight
The 20.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.68x current ratio provides a solid financial cushion.
BIIB Profitability Ratios
BIIB vs Healthcare Sector
How BIOGEN INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BIIB Balance Sheet & Liquidity
BIIB 5-Year Financial Trend
5-Year Trend Summary: BIOGEN INC.'s revenue has declined by 31% over the 5-year period, indicating business contraction. The most recent EPS of $7.97 reflects profitable operations.
BIIB Growth Metrics (YoY)
BIIB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5B | $388.5M | $2.66 |
| Q2 2025 | $2.5B | $583.6M | $4.00 |
| Q1 2025 | $2.3B | $240.5M | $1.64 |
| Q3 2024 | $2.5B | -$68.1M | $-0.47 |
| Q2 2024 | $2.5B | $583.6M | $4.00 |
| Q1 2024 | $2.3B | $387.9M | $2.67 |
| Q3 2023 | $2.5B | -$68.1M | $-0.47 |
| Q2 2023 | $2.5B | $591.6M | $4.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BIIB Capital Allocation
BIIB SEC Filings
Access official SEC EDGAR filings for BIOGEN INC. (CIK: 0000875045)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIIB
What is the AI rating for BIIB?
BIOGEN INC. (BIIB) has an AI rating of HOLD with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIIB's key strengths?
Strong free cash flow generation at $2.1B with 20.7% FCF margin provides capital flexibility. Solid liquidity position with 2.68x current ratio and 2.03x quick ratio supporting operational stability.
What are the risks of investing in BIIB?
Stagnant revenue growth at 2.2% YoY with zero net income growth signals potential product portfolio challenges or market saturation. Significant EPS decline of 21.4% year-over-year despite flat net income suggests share dilution or unfavorable capital allocation.
What is BIIB's revenue and growth?
BIOGEN INC. reported revenue of $9.9B.
Does BIIB pay dividends?
BIOGEN INC. does not currently pay dividends.
Where can I find BIIB SEC filings?
Official SEC filings for BIOGEN INC. (CIK: 0000875045) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIIB's EPS?
BIOGEN INC. has a diluted EPS of $8.79.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.